# Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation

> **NCT00278876** · PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 47 (actual)

## Conditions studied

- Sarcoma
- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Imatinib mesylate (Glivec)

## Key facts

- **NCT ID:** NCT00278876
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2007-08
- **Final completion:** 2011-03
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2020-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00278876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00278876, "Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00278876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*